Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2017-05-01 Director's Dealing
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Transaktioner af ledende medarbejdere samt disses nærtstående
Director's Dealing Classification · 100% confidence The document is a formal notification of share transactions by a person with managerial responsibilities (Novo A/S, related to a board member of Novozymes A/S). It explicitly cites EU Regulation No 596/2014 (Market Abuse Regulation) regarding the disclosure of transactions by persons discharging managerial responsibilities. This falls directly under the category of 'Director's Dealing' (DIRS), which covers insider trades and transactions by company directors and their closely associated persons.
2017-05-01 English
Transaktioner af ledende medarbejdere samt disses nærtstående
Director's Dealing Classification · 95% confidence The document is a formal notification of a transaction in shares by a person discharging managerial responsibilities (Novo A/S, closely associated with a board member). It explicitly cites the Market Abuse Regulation (EU) No 596/2014 and provides detailed tables of share sales, including venues, volumes, and prices. This aligns perfectly with the definition of 'Transaction in Own Shares' or 'Director's Dealing' depending on the entity, but since it involves a major shareholder/managerial entity selling shares, it is classified as a report of share transactions by management/insiders.
2017-05-01 English
Director's Dealing 2017
Director's Dealing Classification · 99% confidence The document text is very short (356 characters) and is written in Danish. It explicitly references EU Regulation No. 596/2014 (Market Abuse Regulation) and states that Novozymes is hereby publishing the following transactions related to its shares (ISIN DK0060336014). It concludes with a link/instruction to 'Read the entire announcement in PDF format' ('Læs hele meddelelsen i PDF format'). This structure—a brief announcement referencing regulatory compliance and pointing to a full document—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content specifically relates to transactions (likely insider trading or major holdings, but the announcement itself is just the publication notice), and given the 'MENU VS MEAL' rule, classifying it as RPA is appropriate if it's announcing the publication of a required disclosure, or RNS as a general regulatory filing. Given the reference to market abuse regulation and publishing transactions, it strongly suggests an insider transaction disclosure (which would normally be DIRS or MRQ), but the text itself is only announcing the publication of that disclosure. Therefore, RPA is the most accurate classification for the announcement wrapper itself.
2017-04-28 Danish
Director's Dealing 2017
Director's Dealing Classification · 99% confidence The document text explicitly details 'Trading by management and of close relations to management' under reference to EU Market Abuse Regulation (MAR) Article 19. It lists specific transactions (Buy/Sell of shares) by an executive (EVP, Agriculture & Bioenergy) on a specific date (2017-04-27). This content directly corresponds to the reporting of personal share transactions by company directors and executives, which matches the definition for Director's Dealing (DIRS).
2017-04-28 English
Transaktioner af ledende medarbejdere samt disses nærtstående
Director's Dealing Classification · 85% confidence The text cites EU Market Abuse Regulation article 19 requiring disclosure of transactions in company shares (Novozymes B, ISIN DK0060336014). This is the mandatory insider dealing report by persons discharging managerial responsibilities (i.e., director’s dealings). It is not a general report publication or interim/annual report. It matches the Director’s Dealing category.
2017-04-28 English
Transaktioner af ledende medarbejdere samt disses nærtstående
Director's Dealing Classification · 100% confidence The document is a formal notification of share transactions by a person discharging managerial responsibilities (PDMR), specifically Tina Sejersgård Fanø, an EVP at Novozymes. It explicitly references EU Market Abuse Regulation (MAR) Article 19, which governs the disclosure of insider dealings. The content details the purchase and sale of shares, transaction dates, prices, and volumes. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2017-04-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.